An interventional study of Continuous vital sign monitoring in Postoperative Care and Deterioration, Clinical, sponsored by Eske Kvanner Aasvang. Not yet recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Eske Kvanner Aasvang · Not applicable, Interventional, and Supportive care
The ONWARD study evaluates user experiences from continuous vital sign monitoring alarms sent to the clinical staff in case of deviating vital signs at the general hospital ward. User experiences are evaluated though a 5-point likert questionnaire.
The ONWARD study evaluates user experiences from continuous vital sign monitoring alarms sent to the clinical staff in case of deviating vital signs at the general hospital ward. User experiences are evaluated though a 5-point likert questionnaire.
The study will focus on adult, hospitalized patients who are monitored at the general hospital ward with continuous, real-time vital sign monitoring combined with the WARD-CSS (WARD clinical support system) that relays alerts to the clinical staff in case of significant deviations. The evaluation focus on the user perceived relevance and usefulness of the alerts generated by the system which includes a proprietary novel alerts logic. Specifically, investigators aim to assess how users evaluate the clinical relevance of triggered change-based alerts and the helpfulness of the accompanying alert descriptions.
During monitoring, the app will be used according to the intended use and additionally two questions will be prompted if alerts are sent.
Patients monitored will have an expected length of stay at the hospital, which supports at least one day of continuous monitoring. Readings from the WARD-CSS is not blinded for treating staff to get feedback on the use of the application. This study will include up to 100 patients.
An alerting feedback questionnaire will be constructed as simple feedback buttons/sliders, prompted after an alert is 'accepted' in the app. The feedback buttons will only be prompted for a representative proportion of the alerts. This will be done at random based on the alert frequencies determined in the retrospective analysis. This way, a close to equal amount of feedback responses will be prompted and obtained for different alert types with different occurrences. The feedback will be linked to the alert in the app, such that feedback can be submitted at any point in time, thus not disturbing the nurse while medical intervention is provided.
The feedback will be constructed with the following two interactions for the clinical staff.
47 studies on the registry are indexed under Clinical Deterioration; 15 are open to participants now.
This study's planned enrollment of 100 is below the median of 375 across 21 interventional studies indexed under Clinical Deterioration.
Browse Clinical Deterioration studies →Eske Kvanner Aasvang is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients can be included if they meet all the following criteria:
Exclusion criteria:
Patients are excluded if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Continuous vital sign monitoring
The intervention involves continuous, real-time vital sign monitoring using sensors to measure vital signs combined with WARD-CSS and novel algorithms designed to detect clinically relevant deviations in the vital signs.
Relevance of alerts
The staff evaluated relevance of alerts triggered during continuous vital signs monitoring Evaluated by 5-point Likert scale: 1\. Not relevant 2 Slightly relevant 3 Moderately relevant 4 Relevant 5 Highly Relevant
Time frame: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
Relevance of the description
Relevance of the description following alerts in relation to the helpfulness in the patient assessment/care Evaluated by 5-point Likert scale: 1. Strongly Disagree 2. Disagree 3- Undecided 4 Agree 5 Strongly Agree
Time frame: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
Alert rate
Total alert rate, including false alert rate, of the WARD-CSS.
Time frame: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
Postoperative complications
Postoperative complications, defined by internationally agreed criteria
Time frame: 30 days
Heart rate (measured in beats per minute (BPM))
Collected continuously
Time frame: 7 days
SpO2 (blood oxygen saturation, measured in percentage)
Collected continuously
Time frame: 7 days
Blood pressure (measured in mmHg)
Collected continuously
Time frame: 7 days
Respiration Rate (measured in BrPM)
Collected continuously
Time frame: 7 days
Pulse (measured in BPM)
Peripheral pulse - Collected continuously
Time frame: 7 days
Temperature (measured in degrees Celcius)
Collected continuously
Time frame: 7 days
Plan to share: Undecided — Data access can be discussed upon request
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Sep 2026, 4 months later.
Of 15 interventional studies with no phase under Clinical Deterioration, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 4 months is below that.
Clinical Deterioration covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eske Kvanner Aasvang